Ghirardi V, Moruzzi MC, Bizzarri N, et al. - Researchers compared patients having advanced ovarian cancer with 1–10 mm residual disease (RD) at primary debulking surgery (PDS) vs those with no gross residual disease (NGR) at interval debulking surgery (IDS), focusing on survival outcomes and perioperative complications. In this analysis, participants were retrospectively included and comprised patients surgically treated with the intent of complete cytoreduction for epithelial ovarian/fallopian tube/primary peritoneal cancer, FIGO stage IIIC-IV, RD 1–10 mm at PDS and NGR at IDS, between January 2010 and December 2016. Participants were 207 in total, including 59 PDS and 148 IDS. The group of PDS vs IDS showed a higher rate of intra- and major early postoperative complications. In the PDS group and in the IDS group, progression/recurrent disease occurred in 48 (81.4%) patients and in 120 (81.1%) patients, respectively. For PDS and IDS groups, the median PFS was estimated to be 16.2 months and 18.9 months, respectively, and the median OS was 41.4 months and 52.4 months, respectively. Taking the superimposable PFS and the decreased number of perioperative complications into account, experts recommended considering IDS as the preferred treatment in case millimetric residual disease is anticipated at PDS.